Member access

4-Traders Homepage  >  Shares  >  SHANGHAI STOCK EXCHANGE  >  Jiangzhong Pharmaceutical Co Ltd    600750   CNE000000M80

End-of-day quote. End-of-day quote SHANGHAI STOCK EXCHANGE - 05/29
40 CNY   +2.25%
 SummaryQuotesChartsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
05/25/2015 05/26/2015 05/27/2015 05/28/2015 05/29/2015 Date
44.29(c) 44.05(c) 42.74(c) 39.12(c) 40(c) Last
8 279 669 8 985 711 9 426 938 8 133 144 7 485 113 Volume
+1.16% -0.54% -2.97% -8.47% +2.25% Change
More quotes
Financials ( CNY)
Sales 2015 3 307 M
EBIT 2015 414 M
Net income 2015 333 M
Finance 2015 603 M
Yield 2015 0,98%
Sales 2016 3 726 M
EBIT 2016 523 M
Net income 2016 416 M
Finance 2016 833 M
Yield 2016 1,10%
PER 2015 36,04
PER 2016 28,43
EV / Sales 2015 3,45x
EV / Sales 2016 3,00x
Capitalization 12 000 M
More Financials
Company
Jiangzhong Pharmaceutical Co. Ltd. is engaged in the manufacture and sale of pharmaceutical products.Main products consist of Chinese, water-soluble and botanical medicines; penicillin injection and raw materials; capsules; antibiotics and others.Other activities include wholesale and retail of... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of Jiangzhong Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on JIANGZHONG PHARMACEUTICAL

- No features available -

More news
Sector news : Pharmaceuticals - NEC
07:38a ROCHE BEARER SHARE : Collaborative group phase III study shows Roche’s Ava..
07:38a ROCHE BEARER SHARE : Updated data showed Roche’s investigational combinati..
07:31a PFIZER : Announces Palbociclib More Than Doubled Progression-Free Survival in Ph..
More sector news : Pharmaceuticals - NEC


Comments 
Advertisement
Chart JIANGZHONG PHARMACEUTICAL
Duration : Period :
Jiangzhong Pharmaceutical  Technical Analysis Chart | 600750 | CNE000000M80 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions